Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways

Ting Lin Yen, Wan-Jung Lu, Li Ming Lien, Philip Aloysius Thomas, Tzu Yin Lee, Hou Chang Chiu, Joen Rong Sheu, Kuan Hung Lin

研究成果: 雜誌貢獻文章同行評審

11 引文 斯高帕斯(Scopus)

摘要

Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (1560 M) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.
原文英語
文章編號728019
期刊BioMed Research International
2014
DOIs
出版狀態已發佈 - 2014

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

指紋 深入研究「Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways」主題。共同形成了獨特的指紋。

引用此